Chronic Lymphocytic Leukaemia

What is Chronic Lymphocytic Leukaemia?

Chronic lymphocytic leukaemia or CLL develops when abnormal B lymphocytes accumulate in the blood, bone marrow and lymphatic tissues. As these cells increase, they may interfere with normal blood cell production and immune function, resulting in anaemia, infections, easy bruising or bleeding.

CLL usually progresses slowly. Hence, many patients do not require treatment immediately after diagnosis.

Types of Chronic Lymphocytic Leukaemia

CLL is generally classified based on the location where the abnormal cells are found and their biological characteristics. These types of CLL are:

Stages of Chronic Lymphocytic Leukaemia

Chronic Lymphocytic Leukaemia (CLL) can be assessed using established clinical staging systems, including the Rai staging system and Binet classification. The Rai system divides CLL into five stages based on lymphocytosis, enlarged lymph nodes, liver or spleen enlargement, anaemia and low platelet counts.

Higher Rai stages generally reflect greater disease involvement or blood-count abnormalities. However, treatment of CLL also depends on symptoms, disease progression, genetic findings and the patient's overall health.

The stages of CLL are indicated in the table below:

How Common is Chronic Lymphocytic Leukaemia in India?

Chronic Lymphocytic Leukaemia is considerably less common in India than in Europe or North America. As per reports, CLL is one of the least common leukaemias in India, accounting for less than 5%.

Globally, CLL accounts for a substantial proportion of adult leukaemia cases, particularly among individuals above 60 years of age. Besides, men are diagnosed more frequently than women.

With increasing life expectancy, improved access to diagnostic facilities and greater awareness of blood cancers, healthcare professionals anticipate that reported CLL cases in India may continue to rise over the coming years.

Symptoms of Chronic Lymphocytic Leukaemia

Many CLL patients have no symptoms during the early stages, and it may first be detected through a routine blood test. Symptoms may gradually develop as abnormal lymphocytes accumulate or normal blood cell production declines.

Some of the common early warning signs and advanced stage symptoms of CLL are listed below:

Disease Similar to Chronic Lymphocytic Leukaemia

CLL may resemble other blood cancers that cause abnormal white blood cell counts, enlarged lymph nodes, fatigue, infections or spleen enlargement. Chronic myeloid leukaemia and mantle cell lymphoma are two such conditions that exhibit some similar symptoms to those of CLL.

A brief comparative overview of these conditions is given below:

CLL Vs. Chronic Myeloid Leukaemia Vs. Mantle Lymphoma

What Causes Chronic Lymphocytic Leukaemia?

The exact cause of CLL is not known. It develops when B lymphocytes acquire DNA changes that allow them to survive and multiply abnormally. These genetic changes usually develop during a person’s lifetime rather than being inherited directly.

Factors associated with a higher likelihood of CLL include:

• Increasing Age: CLL occurs mainly in older adults and is uncommon in people below 40.

• Sex: Men are diagnosed more frequently than women.

• Family History: Having a close relative with CLL or another lymphoid cancer may modestly increase risk.

Most patients have no identifiable risk factor, and CLL is not caused by everyday contact, diet or personal behaviour.

What are the Complications of Chronic Lymphocytic Leukaemia?

Although CLL often progresses slowly, untreated or advanced disease may lead to several complications affecting different organ systems and overall health. These include:

• Recurrent Infections: Reduced immune function increases susceptibility to bacterial, viral and fungal infections.

• Anaemia: Reduced production of healthy red blood cells may cause fatigue, dizziness and breathlessness.

• Thrombocytopenia: Low platelet counts can lead to easy bruising, prolonged bleeding or frequent nosebleeds.

• Enlarged Spleen: Splenomegaly may cause abdominal discomfort and an early feeling of fullness after eating.

• Autoimmune Disorders: The body's immune system may mistakenly attack healthy blood cells, resulting in autoimmune haemolytic anaemia or immune thrombocytopenia.

• Richter Transformation: In a small percentage of patients, CLL may transform into a more aggressive form of lymphoma requiring intensive treatment.

• Secondary Cancers: People with CLL may have an increased risk of developing skin cancers or certain other malignancies due to altered immune surveillance.

Regular monitoring helps detect these complications early and supports timely intervention.

When Should I See My Healthcare Provider?

Because early-stage CLL may not cause noticeable symptoms, it is important to seek medical advice if you experience persistent or unexplained changes in your health.

Consult a healthcare provider if you notice any or multiple of the following:

• Persistent or unexplained swollen lymph nodes

• Repeated or unusually severe infections

• Ongoing fatigue, pallor or breathlessness

• Unexplained bruising or bleeding

• Significant unintentional weight loss

• Persistent fever or drenching night sweats

• Increasing abdominal fullness or discomfort

Individuals already diagnosed with CLL should also seek immediate medical attention if they develop severe infections, sudden breathing difficulty, uncontrolled bleeding or rapidly enlarging lymph nodes.

How is Chronic Lymphocytic Leukaemia Diagnosed?

CLL is usually diagnosed through blood tests and flow cytometry. The diagnosis requires a persistent increase in clonal B lymphocytes in the blood, while additional investigations help assess disease risk and guide treatment.

Commonly used diagnostic methods are given in brief in the table below:

The formal blood criterion for CLL is at least 5 × 10⁹ clonal B lymphocytes per litre, sustained for at least three months and confirmed through flow cytometry. Bone marrow biopsy and routine CT imaging are not required to confirm every case.

How is Chronic Lymphocytic Leukaemia Managed or Treated?

Treatment of chronic lymphocytic leukaemia depends on symptoms, blood counts, disease progression, genetic findings, age, other medical conditions and patient preferences. Some of the management and treatment methods of CLL are mentioned below:

Note: Radiotherapy is not a routine systemic treatment for CLL but may occasionally relieve symptoms from a localised enlarged lymph node or spleen.

Common Medicines Used to Treat Chronic Lymphocytic Leukaemia

Medicines are used when CLL becomes symptomatic or shows clinically significant progression. Commonly used medicines to treat CLL are:

• Ibrutinib: Ibrutinib blocks signals that help abnormal B lymphocytes survive and multiply. It may be used for CLL in selected patients and can provide long-term disease control.

• Acalabrutinib: Acalabrutinib interferes with signals required for CLL cell survival. It is used for adults with CLL and is an established targeted treatment option.

• Zanubrutinib: Zanubrutinib targets signals that support the survival and growth of abnormal B lymphocytes. It may be prescribed for selected patients with CLL.

• Venetoclax: Venetoclax promotes the death of CLL cells by blocking a protein that helps them survive. It may be combined with medicines such as obinutuzumab or rituximab.

• Obinutuzumab: Obinutuzumab attaches to a protein present on abnormal B lymphocytes and helps the immune system destroy these cells. It is commonly used in combination treatment.

• Rituximab: This may be used to target abnormal B lymphocytes and combined with other medicines in specific CLL cases, depending on suitability and disease characteristics.

• Bendamustine: May be combined with rituximab when targeted treatment is unsuitable or inaccessible.

• Fludarabine and Cyclophosphamide: These medicines may be combined with rituximab for a limited group of younger, medically fit patients with favourable biological features.

Note: Medicine selection and dosage depend on disease stage, genetic findings, previous treatment, age, kidney and liver function, other medicines and overall health. These medicines should only be started, stopped or adjusted under the supervision of a qualified haematologist or oncologist.

Living with Chronic Lymphocytic Leukaemia: Daily Challenges and Caregiving

Living with CLL may involve long-term monitoring or treatment. Its effect on daily life depends on disease activity, infection risk, treatment requirements and the patient’s overall health. Some of the daily challenges and crucial care points for CLL patients and families include:

What is the Prognosis for Chronic Lymphocytic Leukaemia?

The prognosis for CLL varies considerably between individuals. Many patients live for years with minimal symptoms and maintain a good quality of life under regular medical supervision. Other patients have biological features that cause faster progression or reduced treatment response.

Several factors influence the prognosis of CLL, including:

• Rai stage

• TP53 mutation or deletion 17p

• IGHV mutation status

• Rate of lymphocyte increase

• Age and overall health

• Response to treatment

Advances in targeted therapies and immunotherapy have significantly improved long-term outcomes for many patients in recent years. Although CLL is generally considered a chronic condition rather than a curable disease, many people achieve prolonged remission and effective disease control with appropriate treatment.

How to Prevent Chronic Lymphocytic Leukaemia?

There is no proven way to prevent CLL because its underlying genetic changes usually develop spontaneously and are not strongly linked to modifiable lifestyle factors.

A balanced diet, regular physical activity, avoiding tobacco and managing long-term health conditions support general health, but they do not specifically prevent CLL. Routine medical care may identify abnormal blood counts and help manage the condition.

Chronic Lymphocytic Leukaemia Treatment Cost in India

There is no fixed treatment cost for all CLL patients, as it depends on the symptoms, health condition, hospital and the city where the treatment is obtained. Some patients may only need regular check-ups and blood tests, while others may need ongoing medicines. Chemotherapy or a stem cell transplant can further increase treatment costs.

An overview of approximate chronic leukaemia treatment costs in India is given below:

Note: Treatment costs for Chronic Lymphocytic Leukaemia (CLL) given above are approximate and may vary based on the treatment plan, disease stage, medicines used, hospital and location. Long-term medicines, specialist consultations, monitoring and management of complications may add to the overall expenses.

Does Health Insurance Cover Chronic Lymphocytic Leukaemia?

Yes. Health insurance policies cover chronic lymphocytic leukaemia, which includes medically necessary hospitalisation, day care treatment, chemotherapy and pre- and post-hospitalisation expenses. Coverage depends on policy terms and conditions, room-rent limits, co-payments, and sub-limits. Moreover, waiting periods may have to be served before filing a claim. If CLL has been diagnosed before policy purchase, a PED waiting period of up to 3 years will apply.

Some insurers offer cancer insurance plans that may provide coverage for early-stage and advanced-stage cancers, depending on the policy terms. Critical illness insurance plans can also be useful as they provide a lump sum benefit upon diagnosis of specified cancer stages, subject to meeting established eligibility criteria. However, they come with a waiting period of up to 90 days and a survival period of up to 30 days.

Since coverage differ across insurers, policyholders should carefully review the policy wording, exclusions and waiting periods before purchasing or making a claim.

How Much Health Insurance Coverage is Needed for Chronic Lymphocytic Leukaemia Treatment?

The amount of health insurance suitable for chronic lymphocytic leukaemia depends on several factors, including disease stage, treatment modality, hospital selection and the city where treatment is received. Expenses may include repeated consultations, advanced diagnostic tests, prolonged medication and hospital admissions.

For many individuals, health insurance coverage of ₹20 lakh to ₹30 lakh may provide meaningful financial support for CLL treatment-related costs. However, for patients at an advanced stage, involving recurrent hospitalisations or stem cell transplants, chemotherapy and other procedures may incur higher expenses. In such situations, a higher coverage amount of ₹50 lakh may be beneficial financially.

It is recommended to review policy terms, coverage and exclusions before planning treatment.